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Objective/background: Generating epidemiological data on multidrug-resistant tuberculosis
(MDR-TB) is essential to assess the magnitude and trends of anti-TB drug resistance. This
study determined the prevalence of MDR-TB among presumptive MDR cases referred to a
TB referral laboratory in the Tigray region of Ethiopia. Methods: A retrospective cross-
sectional study was conducted on 262 culture-positive presumptive MDR-TB samples sub-
mitted to the Tigray Regional Research Laboratory for MDR testing between January 2013
and August 2014. Relevant data were recorded using a structured recording format. Results:
Out of 262 Mycobacterium tuberculosis isolates, 143 (54.6%) were MDR, 28 (10.7%) were resis-
tant to rifampicin only, and 19 (7.3%) were resistant to isoniazid only. The prevalence of
MDR-TB among newly infected cases was 66.7% (8/12) and that among previously treated
cases was 54.1% (97/179). Of the variables tested, being a male was found to be associated
with the development of MDR-TB (p = .003). Conclusion: More than half of the presumptive
MDR cases referred to the Tigray Regional Research Laboratory were MDR. The prevalence
was high in both newly infected and previously treated cases. Hence, re-enforcing the TB
prevention methods, and strengthening the directly observed treatment short-course
(DOTS) strategy and the capacity of laboratories to undertake drug susceptibility testing
(DST) in the region are imperative in order to curb the emergence and transmission of
MDR-TB.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).of Health
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Multidrug-resistant tuberculosis (MDR-TB) is a form of TB
caused by bacteria that are resistant to at least two of the
most powerful first-line anti-TB drugs, isoniazid (INH) and
rifampicin (RIF) [1]. The emergence of MDR-TB has been a glo-
bal health problem threatening the progress made in TB care
and control [2]. Globally, the prevalence of MDR-TB was
reported to be 3.5% among new TB cases and 20.5% among
previously treated TB cases in 2013 [3].
The impact of MDR-TB is much worse in low-income
countries such as Ethiopia, where the socioeconomic status
of the people is low, TB burden is high, and well-equipped
health care facilities are limited [4]. A national drug-
resistance survey conducted in Ethiopia in 2011 reported the
prevalence of MDR-TB to be 2.7% and 17.9% among new and
retreatment cases, respectively [5].
Previous drug resistance surveys involving presumptive
MDR cases reported MDR proportions of 36.3% [6] and 33%,
respectively, in the Amhara and Oromia regions [7] of Ethio-
pia. However, these studies might not be representative of
cases from other regions of the country owing to differences
in lifestyle and environmental conditions across different
regions of Ethiopia [8]. Besides, regions differ in their TB con-
trol and prevention performance. In the annual performance
report of the year 2013/2014, for example, the TB case detec-
tion rates in the Amhara and Oromia regions were about
58% and 61%, respectively, while this figure was about 66%
in the Tigray region [9]. The TB cure rates were 75%, 78%,
and 64% in the Amhara, Oromia, and Tigray regions, respec-
tively [9]. These variations could affect the distribution of
MDR strains, and hence quantifying the burden of MDR-TB
regionally is justifiable. This study, therefore, determined
the prevalence of MDR-TB among presumptive MDR cases
referred to a tuberculosis referral laboratory in the Tigray
region of Ethiopia.
Methods
Study design and setting
This was a health facility-based retrospective cross-sectional
study conducted in the Tigray Regional Research Laboratory
located in Mekelle, the capital of the Tigray region. This regio-
nal research laboratory is the only laboratory that provides
MDR testing service in the Tigray region and is a referral site
for presumptive MDR cases from all parts of Tigray (North
Ethiopia).
Study population and sampling technique
Relevant data were recorded conveniently for all presumptive
MDR cases (treatment failure and relapse cases, defaulters,
and a few new cases) referred to the Tigray Regional Research
Laboratory for MDR testing between January 2013 and August
2014, using a structured recording format. MDR testing was
performed in the regional laboratory by the genotypic method
(Genotype MTBDRplus test, Hain Lifescience) following
the manufacturer’s instructions and standard operatingprocedures. Data on the sociodemographic characteristics,
INH and RIF resistance outcome, previous history of treat-
ment, and previous treatment subcategories were then
extracted from a total of 262 presumptive MDR cases.
Data analysis
Data were entered using Epi Data entry version 3.1
(DenmarkInfo @ EpiData.dk) software and analyzed using SPSS
version 21 (Released 2012. IBM SPSS Statistics for Windows,
Version 21.0. Armonk, NY: IBM Corp). Differences between
the MDR and non-MDR cases with respect to the patients’
baseline characteristics were assessed using the chi-square
test. A p value 6 .05 was considered statistically significant.
Ethical issues
This study was approved by the ethical review committees of
the College of Health Sciences, Mekelle University. A letter of
cooperation was written to the Tigray Regional Research Lab-
oratory authority. Furthermore, confidentiality of patient
information was safeguarded throughout the research
activities.
Results
Characteristics of the study population
Out of the 262 culture-positive presumptive MDR cases
included in this study, 79.4% (208/262) were males and 20.6%
(54/262) females with a mean age of 36 years. The majority
of them (179 [68.3%]) were previously treated cases, while a
few (12 [4.5%]) were newly infected cases. With regard to their
retreatment subcategories, 55.3% (99/179) were relapse cases,
41% (77/179) treatment failure cases, and 3.7% (3/179) default-
ers. However, the TB treatment history was unknown for a
substantial proportion of cases (71 [27.2%]).
Rifampicin and isoniazid resistance patterns
Out of the 262 Mycobacterium tuberculosis isolates, 143 (54.6%)
were MDR, 28 (10.7%) were resistant to RIF only, and 19
(7.3%) were resistant to INH only. The prevalence of MDR-TB
among newly infected cases was 66.7% (8/12) and that among
the previously treated cases was 54.1% (97/179). Within the
previously treated cases, relapse cases had the highest
MDR-TB prevalence (55.6% [55/179]), but the difference was
not statistically significant. Of the variables tested, being a
male was found to be associated with the development of
MDR-TB (p = .003) (Table 1). The prevalence of MDR-TB in
those with an unknown treatment history was 64.8% (46/71).
Discussion
In this study, more than half of M. tuberculosis isolates (54.6%)
were MDR strains. This is notably higher than that docu-
mented in similar reports from the Amhara regional state
(36.3%) [6] and Oromia region (33%) [7]. The difference could
partly be attributed to differences in the TB clinical screening
Table 1 – Association of baseline characteristics with MDR-TB among presumptive MDR-TB cases referred to a tuberculosis
referral laboratory in the Tigray region of Ethiopia between January 2013 and August 2014, as analyzed by the Chi-square
test.
Variables All presumptive MDR cases, n (%) MDR, n (%) Non-MDR, n (%)
n = 262 n = 143 n = 119
Age (y) 0–15 5 (1.9) 3 (60) 2 (40)
16–30 112 (42.7) 59 (52.7) 53 (47.3)
31–45 93 (35.5) 51 (54.8) 42 (45.2)
>45 52 (19.9) 30 (57.7) 22 (42.3)
Chi-square value 2.272
p .893
Sex Male 208 (79.4) 120 (57.7) 88 (42.3)
Female 54 (20.6) 23 (42.2) 31 (57.8)
Chi-square value 8.793
p .003
Previous history of treatment Yes 179 (93.7)a 97 (75.4) 44 (24.6)
No 12 (6.3)a 8 (66.7) 4 (33.3)
Chi-square value 0.768
p .681
Retreatment subcategories Relapse 99 (55.3)b 55 (55.6) 44 (44.4)
Defaulter 3 (3.7)b 1 (33.3) 2 (66.7)
Failure 77 (41)b 41 (53.2) 36 (46.8)
Chi-square value 0.628
p .73
Note: MDR, multidrug resistant; TB, tuberculosis.
p < .05 (significance level).
a The denominator is the total number of presumptive MDR cases with complete data of TB treatment history (75 patients with unknown
treatment history were excluded).
b The denominator is the total number of presumptive MDR cases with a previous history of treatment.
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the annual performance report of the year 2013/2014, the TB
case detection rates in the Amhara and Oromia regions were
about 58% and 61%, respectively, while this figure was about
66% in the Tigray region [9]. This implies that the number of
missed MDR cases in the two regions could be more than that
observed in the Tigray region. In the same report, the TB cure
rate was higher in the Amhara (75%) and Oromia regions
(78%) than in the Tigray region (64%) [9], indicating that we
can expect more MDR cases in Tigray. This indicates that
MDR-TB is a serious public health problem in Ethiopia. Our
figure is, however, comparable to an MDR rate of 53% reported
among presumptive MDR cases in India [10].
We report a high rate of MDR in both newly infected and
previously treated cases. The MDR rate among newly infected
cases (66.6%) is much higher than that documented in previ-
ous reports from Ethiopia [11–13]. The difference could be due
to differences in sample size in that a lower number of new
cases were included in our study. When compared with stud-
ies from other countries, our figure is also higher than those
reported in Kenya [14], Uganda [15], and India [16]. This dis-
crepancy might be due to differences in sample size, study
time, and geographical variation. The high MDR rate in new
cases suggests the existence of active person-to-person trans-
mission of MDR strains in the region and could indicate weak-
ness in TB prevention and control measures.
In the present study, being a male was a risk factor for the
development of MDR-TB. This is in agreement with the report
from Addis Ababa [17]. This association could be due todifferences in the adherence behavior of males and females
to anti-TB treatment. A study in Nigeria, for example, showed
that being a male was a risk factor for defaulting from anti-TB
medication [18], thus increasing their risk of developing MDR-
TB. In contrast to the previous reports from Ethiopia [7,19], in
our study, a previous history of TB treatment was not associ-
ated with the development of MDR-TB.
The proportion of monoresistance to RIF in this study
(10.7%) was also higher than that demonstrated in previous
reports from different parts of Ethiopia [11–13]. The possible
explanation for this difference could be that our study was
conducted in a TB laboratory that is a referral site for pre-
sumptive MDR cases from all parts of Tigray, while the pre-
vious studies involved TB patients seeking routine TB
treatment. Since RIF is the most important drug to treat
TB, emergence of resistance to this drug has huge implica-
tions for TB control policies. This high proportion of
monoresistance suggests that the precursors of MDR-TB
are increasing in the study region as monoresistance to
these drugs predicts MDR. This could negatively impact the
effectiveness of the new RIF-based 6-month treatment regi-
men adopted by the Federal Ministry of Health of Ethiopia.
Hence, efforts are needed to ensure proper use of this drug
in the study region.
To mention some of the limitations, due to the fact that
our study was retrospective in nature, data on the previous
history of treatment weremissing for a substantial proportion
of presumptive MDR cases. Furthermore, since our study
included presumptive MDR cases, generated data might not
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the Tigray region.Conclusion
In conclusion, this study revealed that more than half of the
presumptive MDR cases referred to the Tigray Regional
Research Laboratory were MDR. The prevalence was high in
both newly infected and previously treated cases. Hence, re-
enforcing the TB prevention methods, and strengthening
the DOTS strategy and the capacity of laboratories to under-
take DST in the region are imperative in order to curb the
emergence and transmission of MDR-TB.Conflicts of interest
None.
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